Provided by ProCE, LLC and Clinical and Laboratory Standards Institute (CLSI) in collaboration with the Society of Infectious Diseases Pharmacists (SIDP) and ACCP ID PRN.
The target audience for this activity is pharmacists and laboratory professionals.
At the completion of this activity, the participant will be better able to:
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy.
ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Tanis Dingle, Ph.D., FCCM, D(ABMM): research support: AVIR Pharma
Samuel L. Aitken, PharmD, MPH, BCIDP: consultant/advisor/speaker: Entasis Therapeutics, Shionogi; research support: Melinta Therapeutics
The planners /managers reported the following relationships:
Melissa Johnson: consulting fees, grant support, royalties: Entasis, Merck & Co, Charles River Laboratories, Scynexis
Bruce Jones: consulting/speakers bureau: Paratek, Merck, Melinta, Abbvie, Abbvie, Paratek, LaJolla, Regeneron
ProCE staff and planners have no relevant financial relationships to disclose, except those listed above.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ProCE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-199-H01-P has been assigned to this application-based enduring CE activity. This CE activity is approved for 1.5 contact hour (0.15 CEU) in states that recognize ACPE providers. Completion of the evaluation and the post-test with a score of 65% or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
Clinical and Laboratory Standards Institute is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program.